Acer Saccharum Sap Adenosine Triphosphate Disodium

證據等級: L5

預測適應症: 0 個

Multi-Component Complex (16 Ingredients): Insufficient Data for Drug Repurposing Assessment

One-Sentence Summary

This candidate consists of 16 heterogeneous ingredients — including sugars, bacterial antigens, plant alkaloids, and hormones — with no established regulatory approval in the US and no original indication on record. The TxGNN model generated no predicted indications for this submission, and the Evidence Pack contains critical data gaps that prevent any meaningful repurposing analysis. A Hold decision is recommended until the preparation can be properly characterized.

Quick Overview

Item	Content
Original Indication	Not established (no licensed indications found)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 — model prediction only; currently no supporting data
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction is available for this candidate. The 16 declared ingredients span multiple unrelated pharmacological classes:

Sugars & energy substrates: Acer saccharum sap, dextrose, fructose, lactose, ribose, sucrose, lactic acid
Energy nucleotide: Adenosine triphosphate disodium (ATP)
Polyphenols / phytochemicals: Cinnamic acid, malvin, phlorizin
Hormone: Corticotropin (ACTH)
Spore / plant material: Lycopodium clavatum spore
Bacterial antigens: Salmonella enterica subsp. enterica serovar Enteritidis, Shigella dysenteriae
Inorganic: Silver nitrate

The combination of plant spores, bacterial antigens, and silver nitrate in a sugar matrix is characteristic of homeopathic or nosode preparations, which rely on principles not recognized by conventional pharmacological frameworks. TxGNN operates on a biomedical knowledge graph built from conventional drug–target–disease relationships; such preparations typically fall outside the model’s mapping domain, which explains why no candidates were returned.

Currently, no DrugBank ID exists for this combination, and no mechanism of action data is available. Without a single unified active ingredient that can be mapped to a molecular target, repurposing analysis using TxGNN cannot proceed.

Clinical Trial Evidence

Currently no related clinical trials registered for this multi-component preparation.

Literature Evidence

Currently no related literature available via the standard evidence pipeline.

US Market Information

This preparation has 0 authorizations in the US regulatory system. No NDA, ANDA, or BLA records were found.

Safety Considerations

Please refer to the package insert for safety information.

No safety data — including key warnings, contraindications, or drug interaction records — was retrievable for this candidate. All safety fields were returned as data gaps. Given the presence of corticotropin (a potent hormonal agent) and silver nitrate (a caustic substance) among the declared ingredients, a formal safety review is essential before any clinical consideration.

Conclusion and Next Steps

Decision: Hold

Rationale: This submission cannot be evaluated through the standard TxGNN drug repurposing pipeline because the preparation is an undefined multi-component complex with no DrugBank ID, no licensed indication, and no TxGNN-generated predictions. The heterogeneous ingredient list — combining bacterial antigens, plant spores, sugars, and a corticosteroid — is inconsistent with a single-drug repurposing paradigm.

To proceed, the following is needed:

Preparation characterization: Clarify whether this is a homeopathic, naturopathic, or conventional combination product; confirm if it is a marketed product under a single brand name
Active ingredient identification: Identify the primary pharmacologically active component (if any) and obtain a DrugBank ID for it
Original indication documentation: Establish what condition(s) this preparation is or was intended to treat
Regulatory history review: Determine if this product holds any regulatory status outside the US (e.g., EU HMPC listing, TFDA registration)
Safety review: Assess individual ingredient toxicity, especially corticotropin (systemic ACTH effects) and silver nitrate (cytotoxicity / argyria risk)
Re-submission: Once a single active ingredient is identified, re-run the TxGNN pipeline with that ingredient to obtain valid repurposing predictions

⚠️ Note: Results from this report are for research reference only and do not constitute medical advice. Any drug repurposing candidate requires clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.